Applicable Legal Framework
The year 2026 reshaped the pharmaceutical exclusivity regime in Mexico through three instruments: the amendment to the Federal Law on the Protection of Industrial Property (LFPPI), published in the Official Gazette of the Federation (DOF) on April 3, 2026; the Decree amending the Regulations on Health Supplies (RIS), published on April 24, 2026, and effective as of the following day; and the new LFPPI Regulations, published on April 28, 2026, which took effect sixty business days after their publication and repealed the 1994 Regulations.
With regard to compensation for the period of validity, the LFPPI regulates the complementary certificate in Title II, Chapter VIII (Articles 126 through 136 Bis), and conceives it as one of the means by which the exclusive right of exploitation is granted (Article 36, Section III). The RIS incorporates a parallel mechanism for health-related delays in the new Articles 166-bis 1 through 166-bis 5. With regard to clinical data, Article 168 of the LFPPI refers to applicable legislation and international treaties, and Article 167-bis, paragraph 5, of the RIS establishes the substantive content of the protection.
Compensation for the Term of Pharmaceutical Patents
Delays Attributable to the IMPI
A patent has a non-extendable term of twenty years from the filing date (Article 53 of the LFPPI). As an exception, a supplementary certificate is granted when there are unreasonable delays directly attributable to the Institute that result in a period of more than five years between the filing of the application in Mexico and the grant of the patent (Article 126). The key dates are defined in Article 128: the filing date includes the date of entry into the national phase, and the grant date is the date on which notice of grant is issued.
Regarding admissibility and deadlines, the application is filed only once and independently in response to the notice provided for in Article 110, second paragraph; if filed later, it is untimely and is dismissed outright (Article 129). It must include the case number and relevant dates, the grounds for admissibility, and proof of payment of the fee, with a single five-day deadline (Article 130).
The calculation is performed in three steps (Article 131): (i) verify that the processing period exceeds five years; (ii) subtract reasonable delays; and (iii) if the remaining period still exceeds five years, grant one day of certificate for every two days of unreasonable delay, counted in calendar days (Article 75 of the Regulations). Reasonable delays include the period until a favorable decision on the formal examination, delays attributable to the applicant, the additional time limits under Article 117, delays beyond the Institute’s control (including the adjudication of appeals), and force majeure (Article 132). Article 76 of the Regulations adds the eighteen- and two-month time limits set forth in Articles 107 and 109 of the LFPPI, as well as the time elapsed until the first official action in the substantive examination.
The limitations are clear. The certificate may not exceed five years (Article 127). It takes effect on the day following the expiration of the twenty-year term, provided that the patent is in force (Article 134). It confers the same rights, limitations, and obligations as the patent (Article 135) and expires automatically (Article 136). It is void if it was granted in violation of the applicable provisions or if the patent is revoked or surrendered (Articles 158 and 159).
Delays Attributable to the Health Authority
Article 136 Bis of the LFPPI and Article 166 Bis 1 of the RIS allow for compensation for unreasonable delays by the Ministry of Health, through COFEPRIS, between the filing of the application and the issuance of the health registration, provided that such delays affect the exploitation of a patent identified at the time of filing. Compensation is limited to a single patent per delay and may not exceed five years. The request must be filed by the registration holder within sixty business days following notification of the registration, in accordance with the requirements of Article 166 Bis 2.
Compensation is not applicable if the patent is part of a previously registered drug or was included in an already registered application, if the grant number was not indicated, or if the drug was marketed prior to registration (Article 166 Bis 3). The health authority deducts reasonable delays (Article 166 Bis 4) and communicates its determination to the IMPI. If the determination is favorable, the IMPI issues the certificate (Article 166 Bis 5) upon payment within one month; otherwise, the adjustment is deemed to have been waived (Article 136 Bis). As a reference for the delay, Article 166, Section III, of the RIS establishes a maximum period of one hundred eighty days to resolve applications for new molecules.
Protection of Clinical Data
Technical and scientific information regarding the safety, quality, and efficacy of an allopathic drug containing a New Molecule is protected for five years from the date of notification of the marketing authorization. This protection also extends to information based wholly or partially on a foreign registration, and during that period no third party may use it to obtain a registration without the express written consent of the holder (Article 167-bis, paragraph 5, RIS). A “New Molecule” is defined as a drug, biopharmaceutical, or active ingredient without a marketing authorization in the national territory (Article 2, Section XV, RIS).
With regard to generic drug applicants, Article 167, Section V, of the RIS requires such consent when the interchangeability report is based on data from a New Molecule during the five-year period. Added to this is the link to patents: the applicant must prove ownership of or a license for the patent (Article 167-bis, first paragraph) or declare that it does not infringe on the listed patents. In such cases, the IMPI must issue a decision within ten business days, and its silence is deemed to be a favorable decision (second and third paragraphs). On a substantive level, information submitted to an authority to obtain registrations is not considered to be in the public domain or disclosed by law (Article 163, Section I, LFPPI), which keeps it under the protection of trade secrets.
Interaction Between the Two Concepts
The two concepts are independent in their source and calculation. Compensation extends the patent term; data protection creates regulatory exclusivity that begins upon notification of registration, regardless of whether a patent exists. They complement each other when the patent expires before the five-year data protection period ends, or when data exclusivity expires while the compensated patent remains in force.
Three scenarios of convergence or tension can be identified:
- Accumulation of certificates. A single patent could obtain one certificate due to IMPI delays and another due to health-related delays. Neither regime establishes a combined cap nor rules of priority, although both certificates take effect the day after the patent expires (Articles 134 and 136 Bis).
- The Bolar Exception. Article 57, Section II, of the LFPPI allows third parties to conduct trials during the term of the patent, but such trials do not authorize reliance on the innovator’s protected data. The dispute thus shifts to the application of Article 167-bis of the RIS and to the risk posed by IMPI’s constructive affirmation.
- Challenges. Article 132, Section III, of the LFPPI considers any challenge period to be reasonable, whereas Article 166-bis 4, Section II, of the RIS only considers it so when the decision was not favorable to the applicant. Successfully litigating against COFEPRIS may, therefore, result in compensable time; litigating against the IMPI does not.
Outlook and Challenges
The RIS does not establish a conversion rate between days of delay and days of compensation, unlike the one-to-two ratio set forth in Article 131 of the LFPPI. This omission allows for a wide margin of discretion. Nor is it clear whether the regulatory mechanism, designed for allopathic drugs, applies to biotechnological products, although the definition of “New Molecule” does include biopharmaceuticals. Furthermore, the IMPI’s role in relation to COFEPRIS’s determination appears to be merely one of enforcement, which raises questions about the proper defendant and the appropriate avenue for challenge.
The transitional provisions will be decisive, as pending applications are governed by the provisions in force at the time of their filing (the second transitional article of the RIS and the third transitional article of the Regulations). Added to this is the purification of the patent list, which excludes process patents and must identify the active ingredient by its international name (Article 82 of the Regulations). Everything points to an increase in litigation regarding the calculation of reasonable delays and the invalidity of certificates (Article 158), which will require litigants to meticulously reconstruct the administrative timeline.
REFERENCES:
- Federal Law for the Protection of Industrial Property, as amended on April 3, 2026.
- Regulations under the Federal Law for the Protection of Industrial Property, published on April 28, 2026.
- DECREE amending and supplementing various provisions of the Regulation on Health Supplies. Published on April 24, 2026.
By: Janett Lumbreras



